Questions and answers (Q&A) on regulatory matters related to the introduction and pharmacovigilance of vaccines against COVID-19. 19 January 2021
Fecha
2021-02-01Número de documento
PAHO/IMS/HSS/MT/COVID-19/21-0001
Metadatos
Mostrar el registro completo del ítemOtros idiomas
Resumen
This document provides answers to the most frequently asked questions related to regulatory mechanisms for the approval and post-monitoring approval of COVID-19 vaccines as well as relevant information on the COVAX Facility requirements related to vaccine eligibility. It also summarizes additional guidance on emergency use authorization processes, WHO emergency use listing procedure applied to COVID-19 vaccines, and the role of regulatory authorities during post-approval monitoring of COVID-19 vaccines.
Tema
Colecciones
Esta leyenda debe conservarse, junto con la URL original del artículo.Attribution-NonCommercial-ShareAlike 3.0 IGO
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Summary on Advances in the Development of Vaccines against COVID-19, 3 April 2020
(Washington, D.C., PAHO, 2020-06-03)This document presents a brief summary of vaccines in development for COVID-19. At the end of 2019, the new SARS-CoV-2 coronavirus emerged. Although there is not yet a vaccine against this virus, the field of research for ... -
Recommendations on Regulatory Processes and Aspects related to the Introduction of Vaccines during the COVID-19 Pandemic and Other Emergencies
(Washington, D.C., PAHO, 2021-07-16)The objective of this document is to identify the main gaps in readiness for the introduction of COVID-19 vaccines and to propose the regulatory procedures needed to manage and reduce these gaps, which were detected through ... -
HEARTS in the Americas: Regulatory Pathway to the Exclusive Use of Validated Blood Pressure Measuring Devices
(Washington, D.C., PAHO, 2021-12-15)Cardiovascular disease (CVD) is the leading cause of disease burden globally. According to the 2017 Global Burden of Disease estimates, there were 14 million new cases of CVD, 80 million people living with this condition, ...
